08/05/20 -"Given that the subcutaneous formulation of the lynchpin drug, Darzalex, is now approved by the US FDA, we have increased our estimates for the drug. Also, Ofatumumab has reported positive clinical ..."
Pages
49
Language
English
Published on
08/05/20
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...